Skip to main content

Advertisement

Table 1 Patient characteristics

From: Elevated serum fibroblast growth factor 21 levels correlate with immune recovery but not mitochondrial dysfunction in HIV infection

Age (y) Gender Ethnicity Duration of diagnosed HIV (mo) ART duration (mo) Nadir CD4 count (cells/uL) Current CD4 count (cells/uL) LDS ART (current) ART (lifetime) COX defect (%) Serum FGF-21 (pg/mL)
71 M WB 130 130 UK 530 Y TDF FTC EFV ddi AZT 3TC EFV TDF FTC 3.0% 232
48 F BA 100 99 10 487 N TDF FTC NVP AZT 3TC EFVTDF FTC NVP 0.1% >1920
34 F WB 88 86 218 1121 Y ABC 3TC NVP AZT 3TC NVP ABC 0.0% 560
55 F BA 64 27 112 426 N TDF FTC AZT DRV/r TDF FTC LPV/r AZT DRV/r 0.8% 164
43 M BA 87 87 152 306 N TDF FTC EFV AZT 3TC EFV TDF FTC 0.8% 20
42 M WB 185 147 150 636 N AZT 3TC EFV AZT 3TC NVP 0.0% 342
63 M WB 97 97 169 870 N ABC 3TC EFV AZT 3TC EFV ABC 0.0% 204
29 M WB 84 32 197 401 N TDF FTC EFV TDF FTC EFV 0.0% 809
63 M WB 238 221 NA 438 N ABC 3TC NVP AZT ddl d4T 3TC ddC IDV NVP ABC 2.2% 440
62 M WB 63 62 56 190 N TDF FTC NVP TOP FTC NVP 0.2% 156
52 M WB 225 225 120 728 Y TDF FTC ATV/r AZT ddC ddl 3TC d4T SQV NVP IDV NFV ABC TDF LPV/r FTC ATV/r 1.3% 328
36 M WB 139 138 197 627 N AZT 3TC EFV AZT 3TC EFV TDF FTC 0.3% 214
51 M WB 190 183 10 747 N ABC TDF NVP AZT ddl d4T 3TC RTV NVP IDV ddC ABC ATV/r TDF 4.9% 252
33 F WB 96 95 83 1289 N TDF FTC EFV AZT 3TC EFV TDF FTC 0.0% 177
48 M WB 102 100 259 1329 Y AZT 3TC EFV AZT 3TC EFV 0.4% 409
51 M WB 145 144 151 421 N AZT 3TC NVP AZT 3TC NVP 1.4% 254
66 M WB 71 26 287 455 N TDF FTC EFV TDF FTC EFV 11.2% 470
46 M WB 158 157 250 1452 N TDF FTC EFV AZT 3TC IDV EFV ABC TDF FTC 1.4% 1218
61 M WB 116 113 NA 498 Y TDF FTC NVP AZT 3TC EFV NVP TDF FTC 2.4% 182-
30 M WB 88 23 283 661 N TDF FTC DRV/r TDF FTC EFV DRV/r 0.1% 207
62 M WB 284 202 NA 422 N ABC NVP LPV/r SQV AZT ddC 3TC d4T ddl IDV ABC NVP NFV LPV/r 0.8% 92
45   WB 159 158 176 660 N TDF FTC NVP AZT 3TC IDV NVP TDF FTC 0.0% 60
54 M WB 79 38 244 638 N TDF FTC DRV/r TDF FTC EFV DRV/r 3.4% 178
52 M WB 166 164 0 662 Y TDF FTC NVP AZT d4T IDV NFV SQV 3TC NVP ddl TDF FTC 2.8% 525
51 M WB 243 171 327 539 Y TDF FTC EFV AZT ddl RTV NFV TDF FTC EFV 1.5% 231
35 F BA 62 25 380 638 N TDF FTC EFV TOP FTC EFV 0.0% 82
53 M WB NA 48 301 804 N TDF FTC EFV TDF FTC EFV NA 490
36 M WB 130 130 18 898 N TDF FTC ATV/r AZT 3TC EFV TDF FTC ATV/r 0.0% 530
48 M WB 53 14 332 443 N TDF FTC EFV TDF FTC EFV 0.0% 56
52 F BA 83 81 17 485 Y TDF FTC EFV AZT 3TC EFV TDF FTC 0.7% 224
38 M WB 129 128 4 761 Y TDF FTC EFV AZT 3TC EFV TDF FTC 0.0% 935
47 M WB 183 164 305 668 Y ABC RAL ATV/r d4T 3TC NVP ddl IDV ABC ATV/r RAL 9.8% 114
  1. Summary characteristics of individual HIV-infected subjects. (WB, white British; BA, black African; ART, anti-retroviral therapy; LDS, lipodystrophy syndrome; AZT, zidovudine; d4T, stavudine; ddI, didanosine; ddC, zalcitabine; 3TC, lamivudine; ABC, abacavir; TDF, tenofovir; FTC, emtricitabine; EFV, efavirenz; NVP, nevirapine; ATV, atazanavir; DRV, darunavir; LPV, lopinavir; SQV, saquinavir; NFV, nelfinavir; IDV, indinavir; RTV, ritonavir at therapeutic dose; /r, ritonavir at pharmacokinetic boosting dose; RAL, raltegravir; COX, cytochrome c oxidase; FGF-21, fibroblast growth factor 21; NA, not available).